CarboneC.; PiroG.; TamburrinoA.; MinaM. M.; ZaniniS.; TortoraG.; MelisiD. TGF-β-Activated Kinase 1 (TAK1) Is an In Vivo Druggable Target for Reverting Pancreatic Cancer Chemoresistance. JOP. Journal of the Pancreas, v. 14, n. 5S, p. 562, 15 set. 2013.